Characteristics and results of the aTGA in the 989 patients with an unprovoked first VTE event and 200 controls
| Characteristics . | Patients . | Controls . | P value . |
|---|---|---|---|
| Age (y) | 44.0 (25.0) | 45.0 (26.0) | .375 |
| Sex (male/female) | 259 (26.2)/730 (73.8) | 59 (29.5)/141 (70.5) | .380 |
| PE/DVT | 398 (39.2)/601 (60.8) | ||
| DVT (proximal/distal) | 294 (29.7)/307 (31.0) | ||
| AT deficiency | 13 (1.3) | ||
| PC deficiency | 24 (2.4) | ||
| PS deficiency | 31 (3.0) | ||
| Positive aPLAbs | 89 (9.0) | ||
| Results of the aTGA | |||
| LT_TM–, min | 2.49 [0.72] | 2.79 [1.48] | <.0001 |
| Relative value | 1.15 [0.35] | 1.03 [0.22] | <.0001 |
| V_TM–, nmol·min | 197.6 [138.4] | 112.6 [137.5] | <.0001 |
| Relative value | 1.71 [1.29] | 1.02 [1.10] | <.0001 |
| PH_TM–, nmol·L | 321.9 [138.9] | 230.8 [119.2] | <.0001 |
| Relative value | 1.45 [0.70] | 1.05 [0.46] | <.0001 |
| TTP_TM–, min | 4.53 [1.28] | 4.67 [1.32] | .0577 |
| Relative value | 1.02 [0.29] | 0.99 [0.23] | .226 |
| ETP_TM–, nmol·min | 1629 [543.3] | 1376 [394.9] | <.0001 |
| Relative value | 1.23 [0.42] | 1.03 [0.26] | <.0001 |
| ST_TM–, min | 16.7 [3.67] | 19.48 [3.43] | <.0001 |
| Relative value | 0.89 [0.20] | 1.03 [0.13] | <.0001 |
| LT_TM+, min | 2.80 [1.59] | 2.61 [0.99] | <.0001 |
| TM effect | 1.058 [0.076] | 1.006 [0.100] | <.0001 |
| V_TM+, nmol·min | 187.9 [146.7] | 135.7 [134.5] | <.0001 |
| TM effect | 0.993 [0.188] | 0.795 [0.208] | <.0001 |
| PH_TM+, nmol·L | 259.5 [174.5] | 188.1 [141.8] | <.0001 |
| TM effect | 0.866 [0.230] | 0.654 [0.229] | <.0001 |
| TTP_TM+, min | 4.48 [1.29] | 4.70 [1.81] | <.0001 |
| TM effect | 0.976 [0.072] | 1.023 [0.103] | <.0001 |
| ETP_TM+, nmol·min | 1149 [748.6] | 733.2 [467.3] | <.0001 |
| TM effect | 0.734 [0.309] | 0.506 [0.2-2] | <.0001 |
| ST_TM+, min | 15.0 [2.42] | 15.9 [2.88] | <.0001 |
| TM effect | 0.909 [0.112] | 0.950 [0.131] | <.0001 |
| ETP inhibition, % | 26.61 [30.90] | 42.35 [25.97] | <.0001 |
| Characteristics . | Patients . | Controls . | P value . |
|---|---|---|---|
| Age (y) | 44.0 (25.0) | 45.0 (26.0) | .375 |
| Sex (male/female) | 259 (26.2)/730 (73.8) | 59 (29.5)/141 (70.5) | .380 |
| PE/DVT | 398 (39.2)/601 (60.8) | ||
| DVT (proximal/distal) | 294 (29.7)/307 (31.0) | ||
| AT deficiency | 13 (1.3) | ||
| PC deficiency | 24 (2.4) | ||
| PS deficiency | 31 (3.0) | ||
| Positive aPLAbs | 89 (9.0) | ||
| Results of the aTGA | |||
| LT_TM–, min | 2.49 [0.72] | 2.79 [1.48] | <.0001 |
| Relative value | 1.15 [0.35] | 1.03 [0.22] | <.0001 |
| V_TM–, nmol·min | 197.6 [138.4] | 112.6 [137.5] | <.0001 |
| Relative value | 1.71 [1.29] | 1.02 [1.10] | <.0001 |
| PH_TM–, nmol·L | 321.9 [138.9] | 230.8 [119.2] | <.0001 |
| Relative value | 1.45 [0.70] | 1.05 [0.46] | <.0001 |
| TTP_TM–, min | 4.53 [1.28] | 4.67 [1.32] | .0577 |
| Relative value | 1.02 [0.29] | 0.99 [0.23] | .226 |
| ETP_TM–, nmol·min | 1629 [543.3] | 1376 [394.9] | <.0001 |
| Relative value | 1.23 [0.42] | 1.03 [0.26] | <.0001 |
| ST_TM–, min | 16.7 [3.67] | 19.48 [3.43] | <.0001 |
| Relative value | 0.89 [0.20] | 1.03 [0.13] | <.0001 |
| LT_TM+, min | 2.80 [1.59] | 2.61 [0.99] | <.0001 |
| TM effect | 1.058 [0.076] | 1.006 [0.100] | <.0001 |
| V_TM+, nmol·min | 187.9 [146.7] | 135.7 [134.5] | <.0001 |
| TM effect | 0.993 [0.188] | 0.795 [0.208] | <.0001 |
| PH_TM+, nmol·L | 259.5 [174.5] | 188.1 [141.8] | <.0001 |
| TM effect | 0.866 [0.230] | 0.654 [0.229] | <.0001 |
| TTP_TM+, min | 4.48 [1.29] | 4.70 [1.81] | <.0001 |
| TM effect | 0.976 [0.072] | 1.023 [0.103] | <.0001 |
| ETP_TM+, nmol·min | 1149 [748.6] | 733.2 [467.3] | <.0001 |
| TM effect | 0.734 [0.309] | 0.506 [0.2-2] | <.0001 |
| ST_TM+, min | 15.0 [2.42] | 15.9 [2.88] | <.0001 |
| TM effect | 0.909 [0.112] | 0.950 [0.131] | <.0001 |
| ETP inhibition, % | 26.61 [30.90] | 42.35 [25.97] | <.0001 |
Qualitative data are given as number (%), quantitative results as medians [interquartile range] values.
Results of the aTGA performed in the absence of TM (_TM–) are given as absolute values, then relative values (by referring to a commercial standard plasma tested in parallel). Results of the aTGA performed in the presence of TM (_TM+) are given as absolute values, then TM effect (result without TM divided by the result with TM added). The ETP inhibition parameter is defined as [1 – (ETP_TM+/ETP_TM–)] × 100.
AT, antithrombin; DVT, deep vein thrombosis; LT, lag time; PC, protein C; PE, pulmonary embolism; PH, thrombin peak height; PS, protein S; ST, start tail; TTP, time to thrombin peak; V, velocity index.